Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Pyrvinium |
Synonyms | |
Therapy Description |
Pyrvinium blocks STAT3 and activates CK1-alpha, which leads to CTNNB1 degradation and inhibition of Wnt signaling thereby inducing apoptosis (PMID: 20890287, PMID: 32298693). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pyrvinium | Pyrvinium Pamoate | CTNNB1 Inhibitor 27 STAT3 Inhibitor 26 | Pyrvinium blocks STAT3 and activates CK1-alpha, which leads to CTNNB1 degradation and inhibition of Wnt signaling thereby inducing apoptosis (PMID: 20890287, PMID: 32298693). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC inact mut | colorectal cancer | sensitive | Pyrvinium | Preclinical | Actionable | In a preclinical study, Pyrvinium inhibited Wnt signaling and decreased viability of colon cancer cells harboring APC mutations in culture (PMID: 20890287). | 20890287 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05055323 | Phase I | Pyrvinium | A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer | Recruiting | USA | 0 |